Dicot Pharma Dicot Pharma
På svenska

Phase 2a study Shows Positive Results

The proof of concept study demonstrated that the drug candidate LIB-01 improves erectile function — with sustained effect at week eight.

Sexual dysfunctions

52 percent of men over forty suffer from erectile dysfunction.

  • Home/
  • The Pharmaceutical Project

The Pharmaceutical Project

Dicot Pharma is developing LIB-01 to be a next-generation erectile dysfunction treatment for the global market, aiming to surpass existing drugs. There is a significant medical need for new, improved treatments for erectile dysfunction. With longer duration, fewer side effects, and a differentiated mechanism of action, we aim to provide affected men and couples with an improved intimate life.